Cel Sci (CVM) Asset Utilization Ratio (2011 - 2017)
Cel Sci (CVM) posted Asset Utilization Ratio of 0.02 for Q2 2017, down 4.92% sequentially from 0.02 in Q3 2011.
Cel Sci (CVM) Asset Utilization Ratio (2011 - 2017) Analysis & Trends
Cel Sci has reported Asset Utilization Ratio for 2 years, with the latest figure at 0.02 in Q2 2017.
- Quarterly Asset Utilization Ratio changed N/A year-over-year to 0.02 in Q2 2017, while the trailing twelve-month figure through Jun 2017 was 0.02 (changed N/A YoY) and the FY2011 annual result came in at 0.03, changed N/A from the prior year.
- Asset Utilization Ratio eased to 0.02 in Q2 2017 per CVM's latest filing, from 0.02 in the prior quarter.
- Over five years, Asset Utilization Ratio peaked at 0.02 in Q2 2017 and troughed at 0.02 in Q2 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 0.47 |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 0.38 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 0.20 |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 0.69 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 0.90 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 0.13 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 0.54 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 0.13 |
| 10 | Cel Sci | 2.12 Mn | -4.42 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2017 | 0.02 |
| Sep 30, 2011 | 0.02 |